After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
The new online Learning Center with new content can still be found under the “Training” folder on ...
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...